N01AH03 sufentanil
ATC group of level 5 – chemical substance · in plain English: general anaesthetics
This site has the patient leaflet or the SPC of 4 medicines in this group.
- 4 no longer supplied or not available
Active substance: Sufentanil – all medicines with this substance, also in combinations.
Place in the ATC classification
- N Nervous system drugs 4,479 medicines
- N01 Anesthetics 169 medicines
- N01A Anesthetics, general 71 medicines
- N01AH Opioid anesthetics 27 medicines
- N01AH03 sufentanil 4 medicines
- N01AH Opioid anesthetics 27 medicines
- N01A Anesthetics, general 71 medicines
- N01 Anesthetics 169 medicines
Medicines
| Medicine | Legal category |
|---|---|
| Dzuveo SPC no longer supplied | – |
| Dzuveo 30 micrograms sublingual tablet SPC no longer supplied | – |
| Zalviso SPC no longer supplied | – |
| Zalviso 15 micrograms sublingual tablets SPC no longer supplied | – |
Other groups of the same level
- N01AH01 fentanyl 3 medicines
- N01AH02 alfentanil 4 medicines
- N01AH06 remifentanil 13 medicines
- N01AH51 fentanyl, combinations 3 medicines
Other names of the ATC group
- Czech: N01AH03 Sufentanil
- French: N01AH03 sufentanil
- German: N01AH03 Sufentanil
- German: N01AH03 Sufentanil
- Italian: N01AH03 SUFENTANIL CITRATO
- Polish: N01AH03 Sufentanil
- Turkish: N01AH03 sufentanil
- Portuguese (Brazil): N01AH03 Sufentanilo
- Slovak: N01AH03 Sufentanil
- Spanish: N01AH03 Sufentanilo
- German (Switzerland): N01AH03 Sufentanil
- French (Switzerland): N01AH03 Sufentanil
- Italian (Switzerland): N01AH03 Sufentanil citrato
Sources
- Patient leaflets and SPCs: the MHRA product information (products.mhra.gov.uk) and the European Medicines Agency (EMA)
- Active substances, ATC codes and legal categories: the NHS Dictionary of Medicines and Devices (dm+d), NHS Business Services Authority
- World Health Organization (WHO): ATC/DDD classification, group N01AH03
Contains public sector information licensed under the Open Government Licence v3.0.
Ask your doctor or pharmacist which medicine is right for you.
